Drug
Dostarlimab
Dostarlimab: highest development phase Phase 3, developed by GlaxoSmithKline. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dostarlimab NCT06472076 | Phase 3 | Lung Cancer, Non-Small Cell |
| Dostarlimab NCT05405192 | Phase 2 | Gestational Trophoblastic Neoplasia |
| Dostarlimab NCT06062420 | Phase 2 | Neoplasms, Head and Neck |
Latest
No recent events.
Follow Dostarlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.